A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance

International Journal of Cancer

Volumn 129, Issue 6, 2011, Pages 1425-1434

  Henderson, Paul T ^a,b   Li, Tao ^a   He, Miaoling ^a   Zhang, Hongyong ^a   Malfatti, Michael ^b   Gandara, David ^a   Grimminger, Peter P ^c   Danenberg, Kathleen D ^d   Beckett, Laurel ^a   De Vere White, Ralph W ^a   Turteltaub, Kenneth W ^b   Pan, Chong Xian ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Response Genetics Inc   (United States)

^e VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

accelerator mass spectrometry; chemoresistance; DNA damage; DNA repair; microdosing; platinum chemotherapy

Indexed keywords

CARBOPLATIN;

ACCELERATOR MASS SPECTROMETRY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL ACTIVATION; CELL LEVEL; CONTROLLED STUDY; DNA ADDUCT; DNA CROSS LINKING; DOSE RESPONSE; DRUG MECHANISM; DRUG MICRODOSE; DRUG STRUCTURE; DRUG UPTAKE; EXCISION REPAIR; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; INHIBITORY CONCENTRATION 50; MASS SPECTROMETRY;

EID: 79960914668     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25814     Document Type: Article

References (46)

1. Chaney SG, Campbell SL, Temple B, Bassett E, Wu Y, Faldu M,. Protein interactions with platinum-DNA adducts: from structure to function. J Inorg Biochem 2004; 98: 1551-9. (Pubitemid 39349180)
2. Goodisman J, Hagrman D, Tacka KA, Souid AK,. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 2006; 57: 257-67. (Pubitemid 41779846)
3. Unger FT, Klasen HA, Tchartchian G, de Wilde RL, Witte I,. DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer 2009; 9: 359.
4. Wang D, Lippard SJ,. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-20. (Pubitemid 41130944)
5. Kartalou M, Essigmann JM,. Mechanisms of resistance to cisplatin. Mutat Res 2001; 478: 23-43. (Pubitemid 32530848)
6. Parker RJ, Gill I, Tarone R, Vionnet JA, Grunberg S, Muggia FM, Reed E,. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 1991; 12: 1253-8.
7. Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC, van Oosterom AT, Baan RA, Berends F,. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990; 50: 7887-94.
8. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC,. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987; 84: 5024-8. (Pubitemid 17095857)
9. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC,. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis 1988; 9: 1909-11.
10. Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM,. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 1993; 53: 3694-9. (Pubitemid 23252027)
11. Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, Schmitz PI, Stoter G, Verweij J,. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996; 73: 1569-75. (Pubitemid 26235386)
12. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, Begg AC,. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89: 160-6. (Pubitemid 30185925)
13. Poirier MC, Reed E, Shamkhani H, Tarone RE, Gupta-Burt S,. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect 1993; 99: 149-54. (Pubitemid 23174463)
14. Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R,. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin Cancer Res 1996; 2: 1829-35. (Pubitemid 26384149)
15. Fisch MJ, Howard KL, Einhorn LH, Sledge GW,. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Clin Cancer Res 1996; 2: 1063-6. (Pubitemid 26198476)
16. Motzer RJ, Reed E, Perera F, Tang D, Shamkhani H, Poirier MC, Tsai WY, Parker RJ, Bosl GJ,. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 1994; 73: 2843-52. (Pubitemid 24166275)
17. Blommaert FA, Saris CP,. Detection of platinum-DNA adducts by 32P-postlabelling. Nucleic Acids Res 1995; 23: 1300-6.
18. Welters MJ, Maliepaard M, Jacobs-Bergmans AJ, Baan RA, Schellens JH, Ma J, van der Vijgh WJ, Braakhuis BJ, Fichtinger-Schepman AM,. Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts. Carcinogenesis 1997; 18: 1767-74. (Pubitemid 28134684)
19. Shamkhani H, Anderson LM, Henderson CE, Moskal TJ, Runowicz CD, Dove LF, Jones AB, Chaney SG, Rice JM, Poirier MC,. DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod Toxicol 1994; 8: 207-16. (Pubitemid 2096833)
20. Giurgiovich AJ, Diwan BA, Olivero OA, Anderson LM, Rice JM, Poirier MC,. Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure. Carcinogenesis 1997; 18: 93-6. (Pubitemid 28134621)
21. Gupta-Burt S, Shamkhani H, Reed E, Tarone RE, Allegra CJ, Pai LH, Poirier MC,. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prev 1993; 2: 229-34.
22. Bassett E, King NM, Bryant MF, Hector S, Pendyala L, Chaney SG, Cordeiro-Stone M,. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts. Cancer Res 2004; 64: 6469-75. (Pubitemid 39297902)
23. Hah SS, Stivers KM, de Vere White RW, Henderson PT,. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem Res Toxicol 2006; 19: 622-6. (Pubitemid 43800978)
24. Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson PT,. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem Res Toxicol 2007; 20: 1745-51.
25. Hah SS, Mundt JM, Kim HM, Sumbad RA, Turteltaub KW, Henderson PT,. Measurement of 7,8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry. Proc Natl Acad Sci USA 2007; 104: 11203-8. (Pubitemid 47175119)
26. Turteltaub KW, Felton JS, Gledhill BL, Vogel JS, Southon JR, Caffee MW, Finkel RC, Nelson DE, Proctor ID, Davis JC,. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci USA 1990; 87: 5288-92. (Pubitemid 20260164)
27. Sandhu P, Vogel JS, Rose MJ, Ubick EA, Brunner JE, Wallace MA, Adelsberger JK, Baker MP, Henderson PT, Pearson PG, Baillie TA,. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 2004; 32: 1254-9. (Pubitemid 39410909)
28. Li Y, Shawgo RS, Tyler B, Henderson PT, Vogel JS, Rosenberg A, Storm PB, Langer R, Brem H, Cima MJ,. In vivo release from a drug delivery MEMS device. J Control Release 2004; 100: 211-19. (Pubitemid 39491273)
29. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC,. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006; 80: 203-15. (Pubitemid 44313903)
30. 14C- cobalamin. Proc Natl Acad Sci USA 2006; 103: 5694-9.
31. Fujiwara K, Yamauchi H, Suzuki S, Ishikawa H, Tanaka Y, Fujiwara M, Kohno I,. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother Pharmacol 2001; 47: 22-6. (Pubitemid 32664508)
32. Sharma H, Thatcher N, Baer J, Zaki A, Smith A, McAucliffe CA, Crowther D, Owens S, Fox BW,. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. Cancer Chemother Pharmacol 1983; 11: 5-7. (Pubitemid 13039142)
33. 14C via accelerator mass spectrometry. Anal Chem 2003; 75: 2192-6. (Pubitemid 36542364)
34. Mosmann T,. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63. (Pubitemid 14203433)
35. Gibson UE, Heid CA, Williams PM,. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001. (Pubitemid 26388092)
36. Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM,. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res 2005; 11: 1669-74. (Pubitemid 40315252)
37. 14C-carboplatin. Cancer Chemother Pharmacol 1987; 20: 271-6. (Pubitemid 18007422)
38. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G,. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4731-7. (Pubitemid 46646245)
39. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-91. (Pubitemid 34753602)
40. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y,. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15: 1981-2039.
41. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME,. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070-4.
42. Griffith OW, Meister A,. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979; 254: 7558-60. (Pubitemid 10230219)
43. Westerveld A, Hoeijmakers JH, van Duin M, de Wit J, Odijk H, Pastink A, Wood RD, Bootsma D,. Molecular cloning of a human DNA repair gene. Nature 1984; 310: 425-9. (Pubitemid 14051113)
44. Caras IW, Levinson BB, Fabry M, Williams SR, Martin DW, Jr,. Cloned mouse ribonucleotide reductase subunit M1 cDNA reveals amino acid sequence homology with Escherichia coli and herpesvirus ribonucleotide reductases. J Biol Chem 1985; 260: 7015-22. (Pubitemid 15016091)
45. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G,. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-8. (Pubitemid 46294612)
46. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA,. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204. (Pubitemid 351301852)